翰森制药与罗氏订立许可协议

Core Viewpoint - Hansoh Pharmaceutical (03692) has entered into a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, a CDH17-targeted antibody-drug conjugate, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The agreement involves a payment of $80 million as an upfront fee to Hansoh Pharmaceutical [1] - Hansoh is eligible to receive up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Future potential sales will also generate tiered royalties for Hansoh [1] Group 2: Product and Clinical Trials - HS-20110 is currently undergoing global Phase I clinical trials for the treatment of colorectal cancer (CRC) and other solid tumors in both China and the United States [1] Group 3: Company Background - Roche Holding AG, the parent company of the licensee, is a leading global biotechnology company and a pioneer in the pharmaceutical manufacturing industry, established in 1896 in Basel, Switzerland [1] - The board of Hansoh believes that this licensing agreement aligns with the best interests of the company and its shareholders, maximizing the scientific and commercial value of its technology platform [1]